Radius Health Inc., a Cambridge biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women’s health conditions, said Thursday that it has completed a new equity financing of $43 million.
The financing was led by F2 Biosciences III L.P., with participation from existing investors Biotech Growth N.V., MPM Capital, Brookside Capital, MPM Bio IV NVS Strategic Fund, and BB Biotech Ventures, Radius Health said in a press release.
Radius Health said it plans to use the funding to support the continued advancement of the company’s clinical development programs for its lead asset, BA058, a novel anabolic, bone-building compound for the treatment of patients with osteoporosis at high risk of fracture. BA058-SC, an injectable form of BA058, is currently in a Phase 3 trial. BA058-TD, is in a Phase 2 trial studying the efficacy of delivering BA058 via a transdermal patch.